clinical trial · NCT03989947
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
AchondroplasiaActive BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
brief summary
This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.
started
Jun 12, 2019
primary completion
May 1, 2038
completion
May 1, 2038
last updated
Mar 13, 2026
official title
A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol